Stockhub

Graphite Bio, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

20 September 2022

  • curprev 23:3023:30, 20 September 2022 95.149.241.133 talk 911 bytes +911 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency synd..."
Retrieved from "https://stockhub.co/research/Graphite_Bio,_Inc."